The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-15. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
On 22 April 2003, The Daily Telegraph published news articles and comment describing documents found by its reporter David Blair in the ruins of the Iraqi Foreign Ministry. The documents purported to be records of meetings between Galloway and Iraqi intelligence agents, and they stated that he had received £375,000 per year from the proceeds of the United Nations (UN) Oil-for-Food Programme. Galloway denied the claims and pointed to the nature of the discovery within an unguarded, bombed-out building as being questionable. He successfully sued the newspaper for libel (see below). The Christian Science Monitor also published a story on 25 April 2003, stating that it had documentary evidence that Galloway had received "more than ten million dollars" from the Iraqi government. However, on 20 June 2003, the Monitor reported that its own investigation had concluded that the documents were sophisticated forgeries. In January 2004, it was reported that documents from Iraq's oil ministry showed that Galloway's Mariam Appeal received money from businessmen who had had allegedly illicitly siphoned profits from the UN oil-for-food program. Galloway said that money had been paid into the Mariam Appeal by Iraqi businessmen who had profited from the UN-run programme. He stated he had not benefited personally and that there was nothing illicit about the transaction:
=== Incidence === Beta thalassemia is most prevalent in the "thalassemia belt" which includes areas in Sub-Saharan Africa, and the Mediterranean extending into the Middle East and Southeast Asia. This geographical distribution is thought to be due to the beta-thalassemia carrier state (beta-thalassemia minor) conferring resistance to malaria. In 2005, it was estimated that 1.5% of the world's population are carriers and 60,000 affected infants are born with the thalassemia major annually.
== Current research == Since the Human Genome Project developed a blueprint of all human genes in our chromosomes, proteomics researchers have pushed to understand how that blueprint creates life. Diseases and infections are often the result of proteins going wrong, and finding the aberrant one requires sifting through thousands of other proteins. In addition, many problem proteins have not been given names yet or are too rare to find easily. In the last few years, Smith and his team have led work that has reduced analytical steps from hours to minutes. This increased speed has enabled many samples to be processed faster in high-throughput experiments. Smith has led other advances in sensitivity and accuracy that have improved the ability to find rare proteins, bringing proteomics technology to the doorstep of clinical researchers. Smith and collaborators have applied the technology to liver disease and cancer in the hopes of finding rare markers of disease in blood, making diagnosis or treatment safer and faster. In 2007, Scientific American magazine listed Smith and his collaborator Desmond Smith as one of the top 50 researchers for work to understand the origins of Parkinson's disease by mapping where proteins amass in diseased mouse brains. Among other work, Smith and colleagues at PNNL looked at how bacteria and viruses might cause illness. They've learned breast cancer leaves traces in the blood that doctors might research on someday. Smith led early studies for DOE into possible roles for microbes in making biofuels.
Sources: en.wikipedia.org
=== Al–Am === Bruce Alberts (b. 1938). American biochemist at UC San Francisco, known for his work on protein complexes that enable chromosome replication in science, public policy, and as an original author of the textbook Molecular Biology of the Cell. Member Natl. Acad. Sci. USA. Robert Alberty (1921–2014). American physical biochemist at MIT, noted for many contributions to enzyme kinetics, including early studies of reactions with two substrates. Member Natl. Acad. Sci. USA. Dario Alessi (b. 1967). British biochemist at the University of Dundee known for work on protein kinases. Mary Belle Allen (1922–1973). American botanist at UC Berkeley known for demonstrating the role of chloroplasts in photosynthesis. Jorge Allende (b. 1934). Chilean biochemist at the University of Chile, known for contributions to the understanding of protein biosynthesis and how transfer RNA is generated. Member Natl. Acad. Sci. USA. C. David Allis (1951–2023), US biologist at the Rockefeller University who worked on chromatin. Richard Amasino (b. 1956). American Professor of Biochemistry and Genetics at the University of Wisconsin–Madison, who studies vernalization. Member Natl. Acad. Sci. USA. Bruce Ames (1928–2024). Biochemist and microbiologist at UC Berkeley. He is an expert on mutagenicity and an inventor of the Ames test. Awarded the National Medal of Science John E. Amoore (1939–1998). British biochemist and zoologist at UC Berkeley, who postulated the stereochemical theory of olfaction.
The twenty-foot equivalent unit is the volume of the smallest standard shipping container. It is equivalent to 1,172 cubic feet (33.2 m3). Larger intermodal containers are commonly described in multiples of TEU, as are container ship capacities.
=== U.S. federal government actions === In 2002, a panel of toxicologists, including several from EPA, proposed a level of 150 ppb for drinking water in the PFOA contaminated area around DuPont's Washington Works plant. This initially proposed level was much higher than any known environmental concentration and was over 2,000 times the level EPA eventually settled on for the drinking water health advisory. In July 2004, EPA filed a suit against DuPont alleging "widespread contamination" of PFOA near the Parkersburg, West Virginia plant "at levels exceeding the company's community exposure guidelines"; the suit also alleged that "DuPont had—over a 20 year period—repeatedly failed to submit information on adverse effects (in particular, information on liver enzyme alterations and birth defects in offspring of female Parkersburg workers)." In October 2005, a USFDA study was published revealing PFOA and PFOA precursor chemicals in food contact and PTFE products. On January 25, 2006, EPA announced a voluntary program with several chemical companies to reduce PFOA and PFOA precursor emissions by the year 2015. On February 15, 2005, EPA's Science Advisory Board (SAB) voted to recommended that PFOA should be considered a "likely human carcinogen". On May 26, 2006, EPA's SAB addressed a letter to Administrator Stephen L. Johnson. Three-quarters of advisers thought the stronger "likely to be carcinogenic" descriptor was warranted, in opposition to EPA's own PFOA hazard descriptor of "suggestive evidence of carcinogenicity, but not sufficient to assess human carcinogenic potential".
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.